Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AC Immune SAACIU · Entity 6075 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AC Immune SA
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common ShareSEC Table I · non-derivative | Direct | 92,556 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 16,568 · Balance 92,556 F1: On June 11, 2026, the Reporting Person received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP). F2: Includes 66,556 common shares underlying outstanding restricted share units. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.62 · Expires 2036-06-10 | Direct | 38,889 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 38,889 · Balance 38,889 F3: On June 11, 2026, the Reporting Person received share options with respect to 38,889 shares under the SOIP. The share options will fully vest on June 10, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 11, 2026, the Reporting Person received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP).
F2: Includes 66,556 common shares underlying outstanding restricted share units.
F3: On June 11, 2026, the Reporting Person received share options with respect to 38,889 shares under the SOIP. The share options will fully vest on June 10, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 11:10 UTC | AC Immune SA ACIU · Entity 6075 | GrantShare Option (right to buy) · Derivative | 38,889 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001651625-26-000012 · primary_doc.xml · derivative · entry 2 Twyman Roy Ervin · CIK 0002117542 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,889 Underlying: Common Share · 38,889 shares Expires 2036-06-10 F3 · derivative.exercise_date: On June 11, 2026, the Reporting Person received share options with respect to 38,889 shares under the SOIP. The share options will fully vest on June 10, 2027. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 11:10 UTC | AC Immune SA ACIU · Entity 6075 | GrantCommon Share | 16,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001651625-26-000012 · primary_doc.xml · nonDerivative · entry 1 Twyman Roy Ervin · CIK 0002117542 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,556 F1 · shares: On June 11, 2026, the Reporting Person received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP). F2 · price: Includes 66,556 common shares underlying outstanding restricted share units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.